Member Info for DPC1825

I think that's the bar for £14 treatment options.

the results were only published this Morning.

Didn't realise the Quick approval for budesonide - 'The NHS says it can now be prescribed by GPs to treat Covid on a case-by-case basis from today.'

ah that makes sense, thank you! apologies for my poor grasp of the terminology

what I'm trying to get at is Matt isn't the first on the board insinuate that its the 'placebo' they are short of on the Activ-2 trial, which I believe to be incorrect.

If they were to use the same placebo solution across all 7 current Activ-2 trials, and the same statement around 'limited supply' has not been made on the other drugs Activ-2 entry's (Which to my mind it hasn't) we can near categorically state that there has been a limited supply of our 'investigational agent' (SNG001).

And separately given your professional experience have you ever seen a clinical trial have supply issues for a placebo?

@Scinv - would all of the placebo's on Activ-2 be the same? regardless of delivery method?

https://clinicaltrials.gov/ct2/show/NCT04518410?term=ACTIV-2&draw=2

@Matt, the updated Activ-2 protocol was released on 31st March 21 (Dated 22nd Feb 21) stating the same line 'Participation in phase II evaluations of this agent will be restricted to select US sites, due to limited investigational agent/placebo supply.'

@skippys, yes that's the competing Ameins interferon beta -1b trial. Not our own.

Polar have reduced by 250,000 shares which equals 1.25% of Polars holding at 20m and 0.125% of total shares in circulation at 200m ( i think)

@waynesmith - snap!

@Fruitsnveg - if you copy the image into a word doc and enlarge it becomes legible

Dated: 6th April 21

many thanks FloridaJoe - that's very interesting.

For clarity Oakleaf is your understanding that SNG001 will treat the 1.1m Long CV19 sufferers, who have already had CV19?

I somewhat agree with you Doc, if the treatment works it should stop 'Long Covid' regardless.

And I don't see that the treatment is going to be able to assist those who already suffer from Long Covid ie the 1.1m in the UK as you have mentioned below its not designed to repair peripheral damage caused by CV19.

*Or

@Sterland - have you bee unblinded yet? if so, did you receive the placebo of agent?

@K-mac, I would hope this is the case as well

May is certainly a possibility if they wait for the 90 day Long Covid data analysis.

I cant see a situation where it would be June - although I am not qualified to make this assessment.

that's not true Probitatis,

RM has stated himself 'Plan A is to finish the P3 trials and seek approvals'

https://www.youtube.com/watch?v=nhFqeW6sIXg

I cant work out if you are being facetious Woodstock but a successful P2 home trial is not going to add £1.1bn to the value of this company.

IMO only EUA and/or a pre-order will get us to that sort of level. I predict £2.25-£2.5 ps on positive P2 HT. Higher if we receive conformation the HT data is accepted and integrated as part of our ACTIV-2 P2 trial.